Edwards Lifesciences Corp (NYSE: EW)

Edwards Lifesciences Corp is a global leader in structural heart innovation, driven by a mission to improve patient lives through breakthrough technologies. The company specializes in developing and commercializing advanced cardiovascular technologies, focusing on both surgical and transcatheter therapies. Edwards Lifesciences operates in the medical device industry, specifically within the structural heart disease segment, addressing critical unmet needs in cardiovascular care.

The company generates revenue through the sale of its innovative product portfolio, which includes transcatheter aortic valve replacement (TAVR) systems, transcatheter mitral and tricuspid therapies (TMTT), and surgical structural heart technologies. Primary products such as the SAPIEN family of valves, PASCAL transcatheter repair system, EVOQUE tricuspid valve replacement system, and INSPIRIS RESILIA aortic valve are designed to address various cardiovascular conditions. Edwards Lifesciences serves a diverse customer base, including hospitals, cardiac surgeons, interventional cardiologists, and healthcare systems globally.

• Transcatheter Aortic Valve Replacement (TAVR): This segment includes the SAPIEN family of valves, which are designed for lifetime management of patients with severe aortic stenosis. The SAPIEN valves are delivered while the heart is still beating, enabling quicker recovery and improved quality of life for patients. The SAPIEN 3 platform is notable for its transcatheter heart valve in the transcatheter heart valve (THV-in-THV) indication, offering a minimally invasive procedure for high-risk patients. Additionally, the Edwards SAPIEN 3 system and Alterra system provide minimally invasive options for pulmonary valve replacement in patients with congenital heart disease. TAVR products represented 74%, 75%, and 77% of the company's net sales in 2025, 2024, and 2023, respectively.

• Transcatheter Mitral and Tricuspid Therapies (TMTT): This segment focuses on addressing complex unmet needs in mitral and tricuspid disease with a portfolio of repair and replacement technologies. Key products include the PASCAL transcatheter repair system, EVOQUE tricuspid valve replacement system, and SAPIEN M3 mitral valve replacement system. These products are commercially available in Europe, the United States, and Japan, catering to patients with mitral or tricuspid regurgitation. TMTT products represented 9%, 7%, and 4% of the company's net sales in 2025, 2024, and 2023, respectively.

• Surgical Structural Heart: This segment includes innovative surgical therapies designed to treat patients with structural heart disease. Key products include the INSPIRIS RESILIA aortic valve, KONECT RESILIA aortic valved conduit, and MITRIS RESILIA valve. These products are designed to provide durable and effective solutions for patients undergoing surgical procedures. Surgical tissue heart valve products represented 17%, 18%, and 19% of the company's net sales in 2025, 2024, and 2023, respectively.

Edwards Lifesciences holds a strong position within the structural heart disease segment of the medical technology industry. The company competes with divisions of larger companies as well as smaller companies that offer competitive product lines. Key competitors include Medtronic plc and Abbott Laboratories. Edwards Lifesciences differentiates itself through its commitment to transformative product innovation, high-quality clinical evidence, and comprehensive support to ensure excellent real-world patient outcomes. The company's leadership strategy of differentiated innovation, world-class evidence generation, and indication expansion drives guideline and policy evolution, improving patient access and long-term adoption of its products.

The company's customer base includes hospitals, cardiac surgeons, interventional cardiologists, and healthcare systems globally. Edwards Lifesciences does not rely on any single customer, as no single customer accounted for 10% or more of its net sales in 2025. The company's distribution system consists of direct sales forces and independent distributors, tailored to meet the diverse global needs of its customer base. Edwards Lifesciences is committed to providing high-quality products and technologies to customers worldwide, supported by educational symposia, best practices training, and field clinical specialists who work closely with customers in hospitals.